The gut-vascular axis in diabetes: exploring impaired blood flow, cardiovascular disease, and peripheral arterial complications
DOI:
https://doi.org/10.18203/2320-6012.ijrms20253215Keywords:
Gut microbiota, Gut-vascular axis, Type 2 diabetes mellitus, Endothelial dysfunction, Short-chain fatty acids, Trimethylamine-N-oxide, Microbial dysbiosis, Intestinal permeability, Cardiovascular complications, Microbiome-targeted therapyAbstract
The gut-vascular axis-a dynamic, bidirectional interface between the gut microbiota and vascular system-has emerged as a pivotal regulator of metabolic homeostasis and cardiovascular health, especially in the context of type 2 diabetes mellitus (T2DM). This comprehensive review delineates how microbial dysbiosis, compromised intestinal barrier function, and microbial metabolite imbalances contribute to chronic inflammation, endothelial dysfunction, and vascular complications such as atherosclerosis, coronary artery disease (CAD), and peripheral arterial disease (PAD). Key microbial metabolites such as short-chain fatty acids (SCFAs), trimethylamine-N-oxide (TMAO), and secondary bile acids influence insulin resistance and vascular remodeling. The manuscript also highlights the indirect modulatory roles of SGLT2 inhibitors and GLP-1 receptor agonists on gut microbial dynamics and vascular integrity. Current evidence underscores significant inter-individual variability in microbiota profiles, necessitating personalized therapeutic strategies. Despite compelling preclinical data, translational research in human cohorts remains limited. The review further explores cutting-edge microbiome-based therapeutic strategies, including probiotics, fecal microbiota transplantation (FMT), and engineered microbial therapeutics, while identifying critical research gaps in the development of microbiota-targeted interventions for diabetic vascular disease. Overall, the gut-vascular axis is positioned as a promising frontier in precision medicine for metabolic and cardiovascular complications in diabetes.
Metrics
References
Flori L, Benedetti G, Martelli A, Calderone V: Microbiota alterations associated with vascular diseases: postbiotics as a next-generation magic bullet for gut-vascular axis. Pharmacol Res. 2024;207:107334. DOI: https://doi.org/10.1016/j.phrs.2024.107334
Ahmad AF, Dwivedi G, O’Gara F, Caparros-Martin J, Ward NC. The gut microbiome and cardiovascular disease: Current knowledge and clinical potential. Am J Physiol Heart Circ Physiol. 2019;317(5):923-38. DOI: https://doi.org/10.1152/ajpheart.00376.2019
Robles-Vera I, Toral M, Visitación N, Aguilera-Sánchez N, Redondo JM, Duarte J. Protective Effects of Short-Chain Fatty Acids on Endothelial Dysfunction Induced by Angiotensin II. Front Physiol. 2020;11:277. DOI: https://doi.org/10.3389/fphys.2020.00277
Vincenzo FD, Del Gaudio A, Valentina P, Loris RL, Franco S. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med. 2024;19(2):275-93. DOI: https://doi.org/10.1007/s11739-023-03374-w
Antar SA, Ashour NA, Marwa S, Muhammad K, Naira AA, Roaa TZ, et al. Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomed Pharmacother. 2023;168:115734. DOI: https://doi.org/10.1016/j.biopha.2023.115734
Cani PD, Bibiloni R, Knauf C. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-2. DOI: https://doi.org/10.2337/db06-1491
Schenkein HA, Loos BG. Inflammatory mechanisms linking periodontal diseases to cardiovascular diseases. J Clin Periodontol. 2013;40(14):S51-69. DOI: https://doi.org/10.1111/jcpe.12060
Xu J, Liang R, Zhang W, Kuangyi T, Jieyao L, Xianming C, et al. Faecalibacterium prausnitzii-derived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression. J Diabetes. 2020;12(3):224-36. DOI: https://doi.org/10.1111/1753-0407.12986
Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220-30. DOI: https://doi.org/10.1038/nature11550
Zhou Z, Sun B, Yu D, Zhu C. Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus. Front Cell Infect Microbiol. 2022;12:834485. DOI: https://doi.org/10.3389/fcimb.2022.834485
Cox MJ, Cookson WOCM, Moffatt MF. Sequencing the human microbiome in health and disease. Hum Mol Genet. 2013;22(R1):R88-94. DOI: https://doi.org/10.1093/hmg/ddt398
Barnes JA, Eid MA, Creager MA, Goodney PP. Epidemiology and Risk of Amputation in Patients with Diabetes Mellitus and Peripheral Artery Disease. Arterioscler Thromb Vasc Biol. 2020;40:1808-17. DOI: https://doi.org/10.1161/ATVBAHA.120.314595
Rosa F, Sofia DV, Sara N, Flávio R. Diabetic gut microbiota dysbiosis as an inflammaging and immunosenescence condition that fosters progression of retinopathy and nephropathy. Biochim Biophys Acta Mol Basis Dis. 2019;1865(7):1876-97. DOI: https://doi.org/10.1016/j.bbadis.2018.09.032
Iatcu C, Steen A, Covașă M. Gut Microbiota and Complications of Type-2 Diabetes. Nutrients. 2021;14(1):166. DOI: https://doi.org/10.3390/nu14010166
Tanase DM, Gosav EM, Neculae E, Claudia FC, Manuela C, Loredana LH, et al. Role of Gut Microbiota on Onset and Progression of Microvascular Complications of Type 2 Diabetes (T2DM. Nutrients. 2020;12(12):3719. DOI: https://doi.org/10.3390/nu12123719
Saeedi P, Petersohn I, Salpea P. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157. DOI: https://doi.org/10.1016/j.diabres.2019.107843
Qureshi W, Dar MA, Rather MY. New therapy for metabolic syndrome: Gut microbiome supplementation. World J Diabetes. 2024;15(9):1833-6. DOI: https://doi.org/10.4239/wjd.v15.i9.1833
Cronin P, Joyce SA, O’Toole PW, O’Connor EM. Dietary Fibre Modulates the Gut Microbiota. Nutrients. 2021;13(5):1655. DOI: https://doi.org/10.3390/nu13051655
Azraida H, Swathi NL, Ali A. Immunological insights into nutritional deficiency disorders in Causes and Management of Nutritional Deficiency Disorders. 2024;60-83.
Gandhi A, Rajkumar R, Dakka SN, Sania J, Khurram F, Cabrera J, Swathi NL. Mindfulness training for cardiovascular health in type 2 diabetes: A critical review. Curr Probl Cardiol. 2024;49(12):102833. DOI: https://doi.org/10.1016/j.cpcardiol.2024.102833
Sun H, Saeedi P, Karuranga S, Moritz P, Katherine O, Bruce BD. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2023;183:109119. DOI: https://doi.org/10.1016/j.diabres.2021.109119
Swathi NL, Basavan I, Muzzamil M, Venkatesan A, Rama GS, Arun A. Ch 14. Precision medicine and epigenetics: Personalized diabetes care in Biomedical Research Developments for Improved Healthcare, edi 1. 2024;288-309. DOI: https://doi.org/10.4018/979-8-3693-1922-2.ch014
NL S, Shakhatreh Z, Tahir A, Jasmeet S, Samia S, Athul H, et al. Epigenetic Mechanisms in the Transfer of Metabolic Disorders: A Comprehensive Review. Cureus. 2025;17(3):e80418. DOI: https://doi.org/10.7759/cureus.80418
Wu J, Yang K, Fan H, Wei M, Xiong Q. Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023;14:1114424. DOI: https://doi.org/10.3389/fendo.2023.1114424
G RS, K R, N S. Gut microbiota, metabolic dysregulation, and the role of gut-vascular axis in diabetes. J Physiol. 2020;599:1-12.
Ahmad A, Yang W, Chen G, Shafiq M, Javed R, Ali Zaidi SS. Role of gut microbiota in cardiovascular diseases and the potential therapeutic perspectives. Am J Physiol Heart Circ Physiol. 2019;14(12):e0226372. DOI: https://doi.org/10.1371/journal.pone.0226372
Ahuja A, Aggarwal S, Aggarwal S, Mehta T. Microbiome-based interventions: Probiotics, prebiotics, and FMT for diabetes management. Curr Diabetes Rev. 2022;18:48-57.
Li WZ, Stirling K, Yang JJ, Zhang L. Gut microbiota and diabetes: From correlation to causality and mechanism. World J Diabetes. 2020;15;11(7):293-308. DOI: https://doi.org/10.4239/wjd.v11.i7.293
Bielka W, Przezak A, Pawlik A. The role of the gut microbiota in the pathogenesis of diabetes. Int J Mol Sci. 2022;23(1):480. DOI: https://doi.org/10.3390/ijms23010480
van Heck JIP, Gacesa R, Stienstra R, Jingyuan F, Alexandra Z, Hermie JMH, et al. The Gut Microbiome Composition Is Altered in Long-standing Type 1 Diabetes and Associates with Glycemic Control and Disease-Related Complications. Diabetes Care. 2022;45(9):2084-94. DOI: https://doi.org/10.2337/dc21-2225
Velmurugan G, Dinakaran V, Rajendhran J, Swaminathan K: Blood Microbiota and Circulating Microbial Metabolites in Diabetes and Cardiovascular Disease. Trends Endocrinol Metabol. 2020;31(11):835-47. DOI: https://doi.org/10.1016/j.tem.2020.01.013
Trøseid M, Andersen GØ, Broch K, Hov JR. The gut microbiome in coronary artery disease and heart failure: Current knowledge and future directions. EBioMedicine. 2020;52:102649. DOI: https://doi.org/10.1016/j.ebiom.2020.102649
Lupu VV, Adam Raileanu A, Mihai CM, Ionela DM, Ancuta L, Iuliana MS, et al. The Implication of the Gut Microbiome in Heart Failure. Cells. 2023;12(8):1158. DOI: https://doi.org/10.3390/cells12081158
Matacchione G, Piacenza F, Pimpini L, Rosati Y, Marcozzi S. The role of the gut microbiota in the onset and progression of heart failure: insights into epigenetic mechanisms and aging. Clin Epigenetics. 2024;16(1):175. DOI: https://doi.org/10.1186/s13148-024-01786-9
Balint L, Socaciu C, Vlad A. The association between gut-derived metabolites and biomarkers of renal and cerebro-vascular damage in type 2 diabetes mellitus patients. Nephrol Dial Transplant. 2024;39(1):gfae069. DOI: https://doi.org/10.1093/ndt/gfae069.1058
Fromentin S, Forslund SK, Chechi K, Aron-Wisnewsky J, Chakaroun R, Nielsen T, et al. Microbiome and metabolome features of the cardiometabolic disease spectrum. Nat Med. 2022;28(2):303-14. DOI: https://doi.org/10.1038/s41591-022-01688-4
Fan Y, Pedersen O. Gut Microbiota in Human Metabolic Health and Disease. Nat Rev Microbiol. 2020;19(1):55-71. DOI: https://doi.org/10.1038/s41579-020-0433-9
Yang S, Cao J, Sun C, Yuan L. The Regulation Role of the Gut-Islets Axis in Diabetes. Diabetes, Metabolic Syndrome and Obesity. 2024;17:1415-23. DOI: https://doi.org/10.2147/DMSO.S455026
Hou K, Wu ZX, Chen XY, Jing-Quan W, Dongya Z, Chuanxing X, et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7(1):135. DOI: https://doi.org/10.1038/s41392-022-00974-4
Tao S, Li L, Li L, Yuan L, Qian R, Min S, et al. Understanding the gut-kidney axis among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls: an analysis of the gut microbiota composition. Acta Diabetol. 2019;56(5):581-92. DOI: https://doi.org/10.1007/s00592-019-01316-7
Byndloss M, Devkota S, Duca F, Niess JH, Nieuwdorp M, Orho-Melander M. The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications-2023 Diabetes. Diabetes Care, and Diabetologia Expert Forum Diabetes. 2024;73(9):1391-410. DOI: https://doi.org/10.2337/dbi24-0028
Wang Y, Wu Y, Sailike J, Sun X, Nabi XH. Fourteen composite probiotics alleviate type 2 diabetes through modulating gut microbiota and modifying M1/M2 phenotype macrophage in db/do mice. Pharmacol Res. 2020;161:105150. DOI: https://doi.org/10.1016/j.phrs.2020.105150
Yao W, Huo J, Ji J, K, Tao P. Elucidating the role of gut microbiota metabolites in diabetes by employing network pharmacology. Molecular Med. 2024;30(1):263. DOI: https://doi.org/10.1186/s10020-024-01033-0
Kootte RS, Levin E, Salojärvi J. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome: A randomized, double-blind, placebo-controlled pilot study. Cell Metab. 2017;26:611-9. DOI: https://doi.org/10.1016/j.cmet.2017.09.008
Smits LP, Bouter KE, Vos WM. Short-term treatment with oral antibiotics increases the gut microbiota resilience after fecal microbiota transplantation. Gastroenterology. 2018;154:1577-9.
Sata N, Fujita S, Sata M. Effects of Lactobacillus casei on gut microbiota composition and glucose metabolism in diabetes patients. BMC Microbiol. 2017;17:
Roshanravan N, Mahdavi R, Alizadeh E. The effects of butyrate and inulin supplementation on gut microbiota composition in type 2 diabetes mellitus. J Nutr Biochem. 2018;57:132-40.
Allegretti Jr K. Fecal microbiota transplantation in obesity: A randomized, double-blind, placebo-controlled trial. J Clin Invest. 2020;130:2155-65.
Horvath A, Leber B, Feldbacher N. Probiotics and prebiotics in metabolic syndrome: The role of gut microbiota. Diabetes Obes Metab. 2020;22:123-31.
Oraphruek S, Pinyopornpanish K, Junhasavasdikul D. Multispecies synbiotic supplementation improves antioxidant capacity and gut microbiome in individuals with obesity. Clin Nutr ESPEN. 2023;51:95-103.
J C-Z, Nt M, V C. Metformin alters gut microbiota composition in type 2 diabetes patients. Gut. 2017;66:1794-806.
Tsai CK, Chang WW, Chen CL. The effects of liraglutide on gut microbiota composition and metabolic parameters in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2022;186.
Niu Y, Zhu W, Wang Y. Metformin and liraglutide combination therapy alters gut microbiota and improves glucose metabolism in type 2 diabetes. Pharmacol Res. 2023;186.
Akshay A, Gasim RW, Ali TE, Kumar YS, Hassan A. Unlocking the gut-cardiac axis: A paradigm shift in cardiovascular health. Cureus. 2023;15(12):e51039. DOI: https://doi.org/10.7759/cureus.51039
Rajan EJ, Alwar S V, Gulati R. Prospecting the theragnostic potential of the psycho-neuro-endocrinological perturbation of the gut-brain-immune axis for improving cardiovascular diseases outcomes. Front Mol Biosci. 2024;10:1330327. DOI: https://doi.org/10.3389/fmolb.2023.1330327
Pieralice S, Vigevano F, Del Toro R, Napoli N, Maddaloni E. Lifestyle management of diabetes: Implications for the bone-vascular axis. Curr Diab Rep. 2018;18:1-13. DOI: https://doi.org/10.1007/s11892-018-1060-y
Zarębska J, Krasnoborska J, Samojedny S. Gut microbiota and its implications for cardiovascular diseases-a review. J Educ Health Sport. 2024;62:143-57. DOI: https://doi.org/10.12775/JEHS.2024.62.009
Kaur KK, Allahbadia GNK, Mandeep S. Therapeutic clinical implications of crosstalk amongst gut microbiota, bone health, and vascular calcification in chronic kidney disease: A narrative review. Open Access J Endocrinol. 2023;7(1): 000180. DOI: https://doi.org/10.23880/oaje-16000180
Rodrigues F, Ormanji M, Heilberg I, Bakker S, Borst MD. Interplay between gut microbiota, bone health and vascular calcification in chronic kidney disease. Eur J Clin Invest. 2021;51(9):e13588. DOI: https://doi.org/10.1111/eci.13588
Stamenic D, Harrington J, Millar S. Cohort profile update: The Cork and Kerry Diabetes and Heart Disease Study. HRB Open Res. 2023;6:25. DOI: https://doi.org/10.12688/hrbopenres.13626.1
Engelen S, Graaf Y, Stam-Slob MC: Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes. Int J Cardiol. 2017;248:301-7. DOI: https://doi.org/10.1016/j.ijcard.2017.07.081
Downloads
Published
How to Cite
Issue
Section
